| Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. | |
| | |
MedLine Citation:
|
PMID: 9316692 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 +/- 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200. |
| | |
Authors:
|
J P Hammerstad; W R Woodward; J G Nutt; S T Gancher; G A Block; G Cyhan |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 17 ISSN: 0362-5664 ISO Abbreviation: Clin Neuropharmacol Publication Date: 1994 Oct |
Date Detail:
|
Created Date: 1997-10-23 Completed Date: 1997-10-23 Revised Date: 2009-10-06 |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 429-34 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Oregon Health Sciences University, Portland 97201, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Absorption Antiparkinson Agents / administration & dosage*, blood, pharmacokinetics* Biological Availability Carbidopa / blood, pharmacokinetics*, pharmacology* Delayed-Action Preparations Drug Combinations Humans Levodopa / blood, pharmacokinetics*, pharmacology* Parkinson Disease / drug therapy*, metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Antiparkinson Agents; 0/Delayed-Action Preparations; 0/Drug Combinations; 0/Levodopa; 0/carbidopa, levodopa drug combination; 38821-49-7/Carbidopa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Can nimodipine affect progression of motor neuron disease? A double-blind pilot study.
Next Document: Discontinuation of prolonged bromocriptine therapy in Parkinson's disease patients with uncontrolled...